Abbott Laboratories (ABT)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 8,043,000 | 10,173,000 | 10,578,000 | 7,203,000 | 16,737,000 |
Revenue | US$ in thousands | 39,431,000 | 43,093,000 | 42,541,000 | 34,070,000 | 31,164,000 |
Gross profit margin | 20.40% | 23.61% | 24.87% | 21.14% | 53.71% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $8,043,000K ÷ $39,431,000K
= 20.40%
Abbott Laboratories' gross profit margin has shown a declining trend over the past five years. The margin decreased from 58.53% in 2019 to 55.18% in 2023. This indicates that the company's cost of goods sold has been increasing relative to its revenue, resulting in lower gross profits as a percentage of sales. It is important for the company to closely monitor and manage its cost structure to improve its profitability.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
16.39%
Alkermes Plc
ALKS
39.97%
Amphastar P
AMPH
54.49%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
-6.84%
Biomarin Pharmaceutical Inc
BMRN
78.31%
Bristol-Myers Squibb Company
BMY
37.71%
Catalent Inc
CTLT
21.75%
Catalyst Pharmaceuticals Inc
CPRX
45.19%
Collegium Pharmaceutical Inc
COLL
70.92%